Purpura Treatment Market Research Report- Global Forecast To 2027

Purpura Treatment Market Information, by type (nonthrombocytopenic, thrombocytopenic) by drugs (corticosteroids, intravenous immunoglobulin (ivig), romiplostim (nplate), eltrombopag (promacta)) - Forecast to 2027

ID: MRFR/Pharma/1210-HCR | February 2021 | Region: Global | 80 pages

Study objectives of the Purpura Treatment Market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the purpura treatment market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to the main geography and various regions globally.

  • To provide regional level analysis of the market with respect to the current market size and future prospective

  • To provide regional level analysis of the market for segments by type, by drugs and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the purpura treatment market.


Purpura treatment market, by Region


 


 Intended Audience



  • Pharmaceutical manufacturers & Suppliers

  • Purpura treatment products manufacturers & Suppliers

  • Pharmaceutical and biotechnology companies

  • Hospitals and diagnostic centers

  • Clinics

  • Academic research institutes

  • Government institutes


Market Scenario:


The globally market for purpura treatment is one of the steady growing markets. Purpura occurs when the blood vessels and blood pools under the human skin, result in purple spots on the skin. There are various causes for purpura disease such as disorders that affect blood clotting, weak blood vessels, inflammation in the blood vessels, telangiectasia or Ehlers-Danlos syndrome. Globally the market for purpura treatment is expected to grow at the rate of about XX% from 2016 to 2022.


Key Finding



  • The purpura treatment global market is expected to reach $XX million by 2022.

  • Corticosteroid holds the largest share of XX% of the purpura treatment market.

  • North America holds the largest market share of XX% of purpura treatment’s and is expected to reach $XX billion by the end of forecast period.

  • Asia Pacific is expected to be the fastest growing market at a CAGR of XX%


Segments: 

Purpura treatment market has been segmented on the basis of type which comprises of nonthrombocytopenic and thrombocytopenic. On the basis of drugs, the market is segmented into Corticosteroids, Intravenous immunoglobulin (IVIG), romiplostim (Nplate), eltrombopag (Promacta) and others.


Regional Analysis of Purpura treatment Market:                                                   


Globally North America is the largest market for purpura treatment market. The North American market for purpura treatment is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for purpura treatment which is expected to grow at a CAGR of XX%. Asia pacific region is expected to be fastest growing region in purpura treatment market.


Key Players for Purpura treatment Market:


Some of the key players in this market are: Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc, and others.


The report for Purpura treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   type and drugs
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc,
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions
  Key Market Drivers   Technological advancement, macro economical and governing factors


Frequently Asked Questions (FAQ) :


High prevalence and rising per-capita healthcare expenditure are major tailwinds pushing the growth of the global purpura treatment market.

Stringent government regulations and the lack of awareness about the conditions are major growth impeders for the global purpura treatment market.

North America holds the largest share in the global purpura treatment market, followed by Europe and the Asia Pacific, respectively.

Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Sanofi Winthrop Industrie (U.S.), Hovione (Portugal), F. Hoffman-La Roche AG (Switzerland), Grifols Biologicals Inc. (U.S.), and Amgen Inc. (U.S.), are some of the top players operating in the global purpura treatment market.

Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global Purpura treatment market adopt to gain a larger competitive advantage.

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Challenges

4.4 Opportunities

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining power of suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6 Global Purpura Treatment Market, By Type

6.1 Non-thrombocytopenic Purpura

6.2 Thrombocytopenic Purpura

6.3 Allergic Purpura

7 Global Purpura Treatment Market, By Cases

7.1 Acute

7.2 Chronic

8. Global Purpura Treatment Market, By Treatment

8.1 Corticosteroids

8.2 Intravenous Iimmunoglobulin

8.3 Other Drug Therapies

8.3.1 Romiplostim (Nplate)

8.3.2 Eltrombopag (Promacta)

9 Global Purpura Treatment Market, By Regions

9.1 Americas

9.1.1 North America

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 South America

9.2 Europe

9.2.1 Western Europe

9.2.1.1 Germany

9.2.1.2 France

9.2.1.3 UK

9.2.1.4 Italy

9.2.1.5 Spain

9.2.1.6 Rest of Western Europe

9.2.2 Eastern Europe

9.3 Asia Pacific

9.3.1 Japan

9.3.2 China

9.3.3 India

9.3.4 Australia

9.3.5 Republic of Korea

9.3.6 Rest of Asia-Pacific

9.4 Middle East & Africa

9.4.1 UAE

9.4.2 Saudi Arabia

9.4.3 Qatar

9.4.4 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Company Share Analysis

10.2 Key Development Landscape

10.2.1 Mergers & Acquisitions

10.2.2 Partnerships & Agreements

10.2.3 New Product Launch

10.2.4 Others

11 Company Profile

11.1 Amgen Inc

11.1.1 Company Overview

11.1.2 Product/Business Overview

11.1.3 Financial Overview

11.1.4 Key Developments

11.2 Bristol-Myers Squibb Company

11.2.1 Company Overview

11.2.2 Product overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.3 F. Hoffman-La Roche

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.4 GlaxoSmithKline Plc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.5 Grifols Biologicals Inc

11.5.1 Company Overview

11.5.2 Product overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Hovione

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Novartis AG

11.7.1 Company Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.8 Pfizer Inc.

11.8.1 Company Overview

11.8.2 Product Overview

11.8.3 Financial Overview

11.8.4 Key Developments

11.9 Sanofi

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial Overview

11.9.4 Key Developments

12 Bibliography